secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantheus Holdings, Inc. (LNTH)
CIK:        0001521036
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001193125-24-139440
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantheus appoints new CMO and CSO; Humphrey and Provost roles change May 28
---------------------------------------------------------------------------

- Jeffrey S. Humphrey, MD appointed Chief Medical Officer; Jean-Claude Provost, MD named Chief Science Officer, both effective May 28, 2024.
- Humphrey brings 30+ years clinical oncology experience from Bayer, Bristol-Myers Squibb, Kyowa Kirin, and Pfizer.
- Provost transitions from CMO to CSO to lead business development and pipeline acceleration; holds medicine degree from Sorbonne University.
- CEO Markison says moves will 'enable our team to accelerate innovation' in radiopharmaceutical diagnostics and therapeutics.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/0001193125-24-139440-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1521036/000119312524139440/d824247d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-139440

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer